Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MedImmune -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (316)	5/20/2004 1:19:14 PM
From: sjemmeri	Respond to of 416

MedImmune Provides Update to Investors at 2004 Annual Shareholders` Meeting May 20, 2004 12:08:00 (ET) GAITHERSBURG, Md., May 20, 2004 /PRNewswire-FirstCall via COMTEX/ -- At its Annual Meeting of Shareholders held today in Gaithersburg, Maryland, MedImmune, Inc. (MEDI, Trade) provided an update on its corporate progress to its investors, and reiterated its 2004 and long-range guidance issued on April 27, 2004. During today's meeting, shareholders approved all proposals outlined in MedImmune's 2004 Proxy Statement, including the reelection of the Board of Directors, the ratification of PricewaterhouseCoopers LLP as the company's auditors, and approval for the 2004 Stock Incentive Plan. Commenting on MedImmune's long-range goals, Mr. Mott told shareholders: "MedImmune is committed to advancing science and medicine to help people live better lives. By focusing on this mission over the next five years, we anticipate having four Phase 3 programs underway in 2005; bringing nine new targets out of research and into clinical development over the next three years; introducing two new products to the market between 2007 and 2009; achieving $2 billion in revenues by 2009; and delivering a five-year compounded annual growth rate in earnings per share of approximately 35 percent by 2009."